Our laboratory is focused on characterizing the essential signaling and metabolic processes that tumor cells hijack and reprogram to promote tumorigenesis and drug resistance. We are particularly interested in understanding the role of lysosomes in these processes. Our long-term goal is to translate this knowledge into lysosome-based pharmacological remedies for the clinic.

Lysosomes are catabolic endosomes that break down macromolecules. Due to this function, they were historically perceived as mere “housekeeping” organelles responsible for disposing of macromolecular waste. However, over the past decade, it has become increasingly evident that lysosomes have critical roles beyond degradation, which frequently becomes dysregulated in tumors. This includes controlling the cellular synthesis of new biomolecules - processes which tumor cells need to rewire in order to grow and survive.

In our lab, we investigate how tumor-associated changes in the lysosomal pool affect tumor metabolism, aggressiveness and resistance to therapies. We are particularly interested in the fact that tumor cells often display abnormally increased levels of lysosomes, and to characterize how this drives disease progression. Our work employs cutting-edge imaging techniques, large-scale omics approaches (proteomics, metabolomics, etc.), and classical biochemical methods.

We are increadibly greatful for the support from:

Cancerfonden 

Vetenskapsrådet

Åke Wibergs Stiftelse

Magnus Bergvalls stiftelse

Stiftelsen Lars Hiertas minne